“…In the past year, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been at the forefront of clinical development during the COVID-19 pandemic [ 1 , 2 ]. Also, antiviral agents, treatments to reduce the severity of COVID-19, and therapeutic monoclonal antibody therapies have undergone accelerated approvals worldwide [ 1 , 3 ]. The latest approach to controlling the severity of the clinical effects of SARS-CoV-2, which is now endemic among populations who may not be vaccinated or be clinically vulnerable, would be to neutralize the antibody in recently infected or exposed individuals [ 4 ].…”